Nascent Biotech Stock Price, News & Analysis

Nascent Biotech, Inc. (NBIO) is a clinical-stage biotechnology company in the pharmaceutical preparation manufacturing industry. According to company disclosures, Nascent Biotech focuses on the development of human monoclonal antibodies intended for the treatment of various cancers, and in some descriptions also notes potential applications in viral infections. Its common stock is quoted on the OTCQB market under the symbol NBIO, and the company describes itself as a phase 2 clinical-stage biotech organization.

The company’s business is centered on a single lead clinical candidate, Pritumumab (PTB), a natural human monoclonal antibody. Nascent Biotech states that PTB targets cell surface vimentin (also referred to as ectodomain vimentin), a protein reported by the company to be expressed on the surface of epithelial cancers and overexpressed in brain and pancreatic cancers as well as other hard tumor cancers. The company characterizes PTB as a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells.

Clinical development focus

Nascent Biotech reports that Pritumumab has progressed through a Phase I clinical trial in brain tumor patients, including glioblastoma, where the company states that safety was observed across multiple ascending dose cohorts and that early clinical activity was seen in some patients. Based on company announcements, PTB has been cleared by the U.S. Food and Drug Administration (FDA) to begin Phase II clinical trials for brain cancer, including glioblastoma. Nascent describes itself as a phase 2 clinical-stage company because of this regulatory status, and notes that its products are not yet commercially available.

The company has highlighted that Pritumumab has demonstrated a capacity, in its internal and referenced work, to cross the blood–brain barrier and to act as a monotherapy and as a potential conjugate carrying other therapies. Nascent Biotech has announced that it holds intellectual property, including a method-of-use patent issued by the Japanese Patent Office related to PTB’s ability to cross the blood–brain barrier. The company views this patent as strengthening its intellectual property position and extending protection internationally.

Mechanism and potential applications as described by the company

In its public communications, Nascent Biotech explains that Pritumumab is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. The company states that PTB targets extracellular vimentin on tumor cells, and that this target is present on many epithelial cancers. The company has also reported that PTB has shown the capacity, in preclinical experiments, to cross the blood–brain barrier and potentially transport conjugated drugs into brain tissues.

Nascent Biotech has described plans to evaluate PTB in recurrent and newly diagnosed glioblastoma in Phase II clinical trials. Company materials also reference expanded access plans that would investigate PTB in digestive cancers such as pancreatic and colon cancers. In some communications, Nascent notes that it has received Orphan Drug Designation for pancreatic cancer, and that vimentin expression and PTB’s targeting mechanism suggest potential broader applications across vimentin-positive solid tumors, though these remain in the research and development stage.

Collaborations and research initiatives

Nascent Biotech has announced several collaborations designed to expand the potential uses of Pritumumab. In one collaboration with Manhattan BioSolutions, Inc., the company reports that it is exploring antibody-drug conjugates (ADCs) using PTB as the tumor-targeting antibody element. Under that agreement, Manhattan BioSolutions is expected to perform PTB conjugations to industry-standard linker–payloads and evaluate resulting ADCs in cell-based assays, with promising candidates prioritized for further development in advanced or metastatic tumors.

In another collaboration, Nascent Biotech has reported working with HypoSpray Pharma on a proprietary transdermal and transmucosal delivery system. According to Nascent’s description, this collaboration aims to develop an alternative delivery mechanism for Pritumumab that could, if successfully developed and commercialized, reduce or eliminate the need for recurrent infusion-center visits by enabling administration through HypoSpray’s delivery technology. The company presents this as a potential way to improve patient convenience and quality of life, though this remains a development-stage effort.

Clinical data presentations and regulatory milestones

The company has reported that its Phase I clinical data for Pritumumab in brain tumors were presented at the American Society of Clinical Oncology (ASCO) annual meeting in a poster format. Nascent Biotech summarizes these data as demonstrating safety across five ascending dose cohorts and showing biological activity in several patients. The company has also announced that the FDA has cleared it to begin Phase II clinical trials for brain cancer, which Nascent describes as a key development milestone in advancing PTB through the regulatory process.

Nascent Biotech’s communications emphasize that Phase II research will focus on clinical outcomes in glioblastoma and other brain tumors, following the safety-focused Phase I trial. The company has discussed Phase II designs that include monotherapy arms and combination arms with chemotherapy and checkpoint inhibitors for recurrent glioblastoma, as well as an arm for newly diagnosed glioblastoma prior to chemoradiation, and expanded access studies in digestive cancers. These descriptions come from the company’s own press releases and presentations.

Intellectual property and scientific positioning

Nascent Biotech underscores the importance of its intellectual property around Pritumumab. The company has announced a Japanese method-of-use patent covering PTB’s ability to cross the blood–brain barrier, and it has also stated that it holds a patent covering PTB’s specialized delivery mechanism in preclinical experiments where PTB has been used to transport conjugated drugs into brain tissues. The company presents these patents and scientific findings as central to its value proposition in the monoclonal antibody and targeted immunotherapy space.

In its descriptions, Nascent Biotech repeatedly characterizes itself as pioneering the development of human monoclonal antibodies for cancer treatment, with PTB as its lead asset. The company has also referenced potential applications in viral infections in some of its “About Nascent” statements, though detailed clinical programs in that area are not described in the provided materials.

Capital structure and trading status as described by the company

Nascent Biotech’s common stock trades under the symbol NBIO on the OTCQB marketplace. In a December 2023 press release, the company announced that it had completed payment of a variable convertible note, stating that this eliminated a source of potential dilution related to that specific obligation. In January 2025, Nascent Biotech disclosed that it received a delinquency notification from OTC Markets Group for not filing a Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, on time. As a result, the company reported that its stock was quoted on the OTC Markets’ Expert Market rather than the regular OTC platforms, and that it expected normal quotation to resume once it became current in its filings and met the marketplace’s requirements.

Nascent Biotech has described itself as a fully reporting company with a history of timely filings over many years, while also acknowledging the more recent filing delay noted in the delinquency notification. The company emphasizes, in its own statements, a focus on shareholder interests and on managing its balance sheet in ways it believes are favorable to existing shareholders.

Business model and stage of development

Based on its public communications, Nascent Biotech’s business model is that of a clinical-stage biotechnology company focused on research and development rather than commercial product sales. The company explicitly notes that its products are not yet commercially available. Its activities, as described, center on advancing Pritumumab through clinical trials, securing and expanding intellectual property protection, and entering into collaborations that may broaden PTB’s therapeutic applications or improve its delivery.

As a clinical-stage organization in the monoclonal antibody space, Nascent Biotech’s value proposition, as presented in its own materials, is tied to the clinical and regulatory progress of Pritumumab, the uniqueness of its targeting of cell surface vimentin, its reported ability to cross the blood–brain barrier, and the potential to serve as a platform for antibody-drug conjugates and alternative delivery approaches. Investors and observers reviewing NBIO typically focus on these development milestones, regulatory clearances, collaboration agreements, and intellectual property updates as key elements of the company’s story.